Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R O Dillman

Showing results (31-40 of 134) with videos related to

Pageof 14
Sort By:
Molecular Biotherapy|September 1, 1992
Phase I cancer trials: limitations and implicationsR O Dillman, J A Koziol
Journal of Biological Response Modifiers|June 1, 1987
Problems associated with radioimmunodetection and possibilities for future solutionsS E Halpern, R O Dillman
Molecular Biotherapy|January 1, 1988
Molecular biotherapy with human monoclonal antibodiesM C Glassy, R O Dillman
Cancer Research|January 1, 1983
Statistical approach to immunosuppression classification using lymphocyte surface markers and functional assaysR O Dillman, J A Koziol
Journal of the National Cancer Institute|March 17, 1993
Primary lymphoma of the kidney: complete remission after systemic chemotherapyL A Vandermolen, R O Dillman
Cancer Biotherapy|January 1, 1995
Cancer clinical trials in the community setting: a 20 year retrospectiveR A Avent, R O Dillman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Intensive chemotherapy with autologous peripheral-blood stem-cell rescue in metastatic breast cancerR O Dillman, N M Barth
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2001
Utilization of breast-conserving surgery in breast cancerR O Dillman, S Chico, S Finestone
Cancer Research|April 1, 1982
Establishment and characterization of an Epstein-Barr virus-negative lymphoma B-cell from a patient with a diffuse large cell lymphomaR O Dillman, H H Handley, I Royston
Cancer Biotherapy & Radiopharmaceuticals|August 1, 1997
The Cancer Biotherapy Research Group [CBRG], formerly the National Biotherapy Study Group [NBSG]: a 10-year perspectiveR O Dillman, R Crispin, R K Oldham
Pageof 14

Showing results (31-40 of 134) with videos related to

Sort By:
Pageof 14
Molecular Biotherapy|September 1, 1992
Phase I cancer trials: limitations and implicationsR O Dillman, J A Koziol
Journal of Biological Response Modifiers|June 1, 1987
Problems associated with radioimmunodetection and possibilities for future solutionsS E Halpern, R O Dillman
Molecular Biotherapy|January 1, 1988
Molecular biotherapy with human monoclonal antibodiesM C Glassy, R O Dillman
Cancer Research|January 1, 1983
Statistical approach to immunosuppression classification using lymphocyte surface markers and functional assaysR O Dillman, J A Koziol
Journal of the National Cancer Institute|March 17, 1993
Primary lymphoma of the kidney: complete remission after systemic chemotherapyL A Vandermolen, R O Dillman
Cancer Biotherapy|January 1, 1995
Cancer clinical trials in the community setting: a 20 year retrospectiveR A Avent, R O Dillman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1994
Intensive chemotherapy with autologous peripheral-blood stem-cell rescue in metastatic breast cancerR O Dillman, N M Barth
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2001
Utilization of breast-conserving surgery in breast cancerR O Dillman, S Chico, S Finestone
Cancer Research|April 1, 1982
Establishment and characterization of an Epstein-Barr virus-negative lymphoma B-cell from a patient with a diffuse large cell lymphomaR O Dillman, H H Handley, I Royston
Cancer Biotherapy & Radiopharmaceuticals|August 1, 1997
The Cancer Biotherapy Research Group [CBRG], formerly the National Biotherapy Study Group [NBSG]: a 10-year perspectiveR O Dillman, R Crispin, R K Oldham
Pageof 14